According to Teikoku, the transdermal formulation is a once-a-week patch that continuously delivers donepezil through the skin into the bloodstream.
It will enable the number of doses to be reduced, make it easier to be used for patients with Alzheimer’s disease who have difficulty in swallowing, and also reduce the burden of caregivers or family members when administering it to patients, the company said.